Wells Fargo analyst Eva Fortea Verdejo initiated coverage of iTeos Therapeutics with an Overweight rating and $31 price target. The firm likes the setup for shares, which offers a compelling risk/reward given where the stock is trading. Wells thinks the Street underappreciates belrestotug and the company’s adenosine pathway molecules and sees upside on multiple catalysts in the second half of 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
- iTeos Therapeutics reports Q2 EPS (96c), consensus ($1.04)
- iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
- iTeos Therapeutics appoints Feltquate as Chief Medical Officer
- iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study